Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Moderate Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $77.1818.

Several equities analysts recently issued reports on VERA shares. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. JPMorgan Chase & Co. cut their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. The Goldman Sachs Group lifted their target price on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $42.74 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. Vera Therapeutics has a one year low of $18.53 and a one year high of $56.05. The stock’s 50 day moving average is $46.70 and its 200 day moving average is $33.04. The firm has a market cap of $2.73 billion, a P/E ratio of -10.71 and a beta of 1.16.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter in the prior year, the company earned ($0.85) EPS. As a group, research analysts expect that Vera Therapeutics will post -2.89 EPS for the current year.

Insiders Place Their Bets

In other news, Director Patrick G. Enright bought 5,882 shares of Vera Therapeutics stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the purchase, the director directly owned 5,882 shares in the company, valued at approximately $249,985. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 16.30% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC increased its position in shares of Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after acquiring an additional 62,678 shares in the last quarter. J. Safra Sarasin Holding AG acquired a new stake in shares of Vera Therapeutics in the 2nd quarter worth about $697,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Vera Therapeutics in the 2nd quarter valued at about $237,000. Institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.